AVRO - AVROバイオ (AVROBIO Inc.) AVROバイオ

 AVROのチャート


 AVROの企業情報

symbol AVRO
会社名 AVROBIO Inc (AVROバイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 AVROBIO Inc. is a clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01 AVR-RD-02 AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.   AVROバイオは米国のバイオ医薬品企業。臨床段階で、主に希少疾患に対する遺伝子治療に焦点を当てた医薬品の開発・商業化に従事する。同社はリソソ―ム蓄積症に対する幹細胞遺伝子治療を開発し、一度の投与で効果を表す医薬品を手がける。パイプラインにはゴ―シェ病、ポンペ病、シスキシン症の治療薬を含む。本社所在地はマサチュ―セッツ州ケンブリッジ。   Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
本社所在地 One Kendall Square Building 300 Suite 201 Cambridge MA 02139 USA
代表者氏名 Bruce Booth ブルースブース
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 781-962-6030
設立年月日 42309
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 34人
url www.avrobio.com
nasdaq_url https://www.nasdaq.com/symbol/avro
adr_tso
EBITDA EBITDA(百万ドル) -31.03900
終値(lastsale) 25.6
時価総額(marketcap) 612783052.8
時価総額 時価総額(百万ドル) 578.31400
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 423.29900
当期純利益 当期純利益(百万ドル) -35.06700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Avrobio Inc revenues was not reported. Net loss applicable to common stockholders increased from $4.7M to $21M. Higher net loss reflects Research and developme increase from $3.3M to $12.9M (expense) General and administrative increase from $1.2M to $3.9M (expense) Gains/Losses on Trading Derivatives increase from $35K to $1.6M (expense).

 AVROのテクニカル分析


 AVROのニュース

   AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis  2020/03/09 11:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s investigational gene therapy, AVR-RD-04, for the treatment of cystinosis. The gene therapy consists of the patient’s own hematopoietic stem cells, which are genetically modified to express cystinosin, the
   AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference  2020/02/24 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the Cowen and Company 40th Annual Health Care Conference at 4:50 p.m. ET on Monday, March 2, 2020, at the Boston Marriott Copley Place, Boston. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors &
   AVROBIO Announces Closing of Underwritten Public Offering  2020/02/18 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 4,350,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled approximately $100 million. As previously announced, the company has granted the underwriters a 30-day
   AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock  2020/02/13 03:08:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 4,350,000 shares of its common stock at a public offering price of $23.00 per share. Gross proceeds from the underwritten public offering will total approximately $100 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted
   AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program  2020/02/10 21:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced new initial data from the first patient dosed in the investigational gene therapy program for cystinosis, showing improvements in early measures at three months compared to baseline. The company also unveiled new clinical data showcasing a sustained biomarker response in patients for up to 32 months after
   AVROBIO EPS in-line  2019-05-13
AVROBIO (NASDAQ: AVRO ): Q1 GAAP EPS of -$0.72 in-line. More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more …
   AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update  2019-05-13 Business Wire
Regulatory clearances achieved that enable integration of the plato platform into Fabry FAB-201 and Gaucher GAU-201 clinical trials in the second half of 2019 IND for AVR-RD-01 for the treatment of Fabry disease cleared by the FDA; AVROBIO plans to open U.S. clinical trial site…
   Janney likes AVROBIO and Amicus in premarket analyst action  2019-04-05
AVROBIO (NASDAQ: AVRO ) initiated with Buy rating at Janney Montgomery Scott. More news on: AVROBIO, Inc., Amicus Therapeutics, Inc., Celgene Corporation, Healthcare stocks news, Stocks on the move, , Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 AVROバイオ AVRO AVROBIO Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)